The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Irit Dinur's journey through mathematics and computer science led her to become the first woman professor at the Institute for Advanced Study.

To that end, Florida Tech has relaunched the underutilized Center for Advanced Manufacturing and Innovative Design as Vertex, a new "applied innovation hub." Rather than function as a traditional ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown its team year-over-year. At a time when many life sciences companies are ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel non-opioid pain medication. This approval marks ...

Now the tricky thing about CF is different gene mutations cause different problems with the protein, but Vertex has managed to develop medicines that are able to treat about 90% of CF patients.